ZA201302363B - Formulations and methods for attenuating respiratory depression induced by opioid overdose - Google Patents

Formulations and methods for attenuating respiratory depression induced by opioid overdose

Info

Publication number
ZA201302363B
ZA201302363B ZA2013/02363A ZA201302363A ZA201302363B ZA 201302363 B ZA201302363 B ZA 201302363B ZA 2013/02363 A ZA2013/02363 A ZA 2013/02363A ZA 201302363 A ZA201302363 A ZA 201302363A ZA 201302363 B ZA201302363 B ZA 201302363B
Authority
ZA
South Africa
Prior art keywords
formulations
methods
respiratory depression
opioid overdose
depression induced
Prior art date
Application number
ZA2013/02363A
Other languages
English (en)
Inventor
Michael J Lamson
Veeraindar Goli
Original Assignee
Alpharma Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals Llc filed Critical Alpharma Pharmaceuticals Llc
Publication of ZA201302363B publication Critical patent/ZA201302363B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2013/02363A 2010-10-26 2013-04-02 Formulations and methods for attenuating respiratory depression induced by opioid overdose ZA201302363B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
ZA201302363B true ZA201302363B (en) 2014-06-25

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/02363A ZA201302363B (en) 2010-10-26 2013-04-02 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Country Status (14)

Country Link
US (3) US20140030343A1 (cg-RX-API-DMAC7.html)
EP (1) EP2632442A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013540807A (cg-RX-API-DMAC7.html)
KR (3) KR20130097211A (cg-RX-API-DMAC7.html)
CN (1) CN103189055A (cg-RX-API-DMAC7.html)
AU (1) AU2011322147A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013009267A2 (cg-RX-API-DMAC7.html)
CA (1) CA2814230A1 (cg-RX-API-DMAC7.html)
IL (1) IL225966A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013003832A (cg-RX-API-DMAC7.html)
RU (1) RU2541159C2 (cg-RX-API-DMAC7.html)
SG (1) SG189234A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012056402A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201302363B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
AU2011322147A1 (en) * 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU2013136350A (ru) * 2011-02-02 2015-03-27 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
FI3800177T3 (fi) 2015-12-22 2025-04-29 Zogenix International Ltd Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
WO2017180659A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) * 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US20240100120A1 (en) * 2019-10-11 2024-03-28 Board Of Regents, The University Of Taxas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US12138267B2 (en) 2021-11-02 2024-11-12 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
EP1694386B1 (en) * 2003-12-05 2017-05-03 CareFusion 303, Inc. Patient-controlled analgesia with patient monitoring system
WO2007044711A1 (en) 2005-10-07 2007-04-19 University Of Florida Research Foundation, Inc. Multiple component nanoparticles for multiplexed signaling and optical encoding
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
AU2008296905A1 (en) * 2007-09-04 2009-03-12 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
BRPI0911715A2 (pt) 2008-07-31 2019-09-24 Alma Mater Studiorum - Universita' Di Bologna partículas ativas para aplicações bio-analíticas e métodos para sua preparação.
AU2011322147A1 (en) * 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Also Published As

Publication number Publication date
WO2012056402A2 (en) 2012-05-03
KR20130097211A (ko) 2013-09-02
WO2012056402A3 (en) 2012-10-04
KR20160017668A (ko) 2016-02-16
RU2541159C2 (ru) 2015-02-10
JP2013540807A (ja) 2013-11-07
IL225966A0 (en) 2013-06-27
BR112013009267A2 (pt) 2016-07-26
US20170367987A1 (en) 2017-12-28
CN103189055A (zh) 2013-07-03
US20140030343A1 (en) 2014-01-30
RU2013117274A (ru) 2014-12-10
AU2011322147A1 (en) 2013-04-18
EP2632442A2 (en) 2013-09-04
KR20170102571A (ko) 2017-09-11
MX2013003832A (es) 2013-10-01
SG189234A1 (en) 2013-05-31
US20160045449A1 (en) 2016-02-18
CA2814230A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
IL225966A0 (en) Preparations for the treatment of respiratory arrest following an opioid overdose
ZA201401526B (en) Method and formulation for inhalation
EP2521584A4 (en) INHALATION DEVICE AND METHOD THEREFOR
IL237258B (en) Methods of treating or preventing asthma by administering an antagonist to -il-r4
IL223118A (en) Inhaler of cure and method for its composition
ZA201304406B (en) Inhalator
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
AU336564S (en) Respiratory mask
EP2621588A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
HUE040353T2 (hu) Inhalátorból és kapszulából álló rendszer
IL221768A (en) From women
EP2741665A4 (en) SEQUENCING EVENTS USING ACOUSTIC RESPIRATORY MARKERS AND ASSOCIATED METHODS
GB201200525D0 (en) An inhalable medicament
IL271284A (en) Methods for treating or preventing asthma by administering an antagonist to -il-r4
AU2011903839A0 (en) Inhalation device and method
HK1192508A (en) Systems and methods for administering an exercise program
AU333535S (en) Respiratory device
GB201007724D0 (en) Respiratory therapy apparatus
AU2010904216A0 (en) Inhalation device and method
AU2011905457A0 (en) Respiratory physiotherapy device
GB201012660D0 (en) Inhaler and formulation
AU2011903049A0 (en) Method and formulation for inhalation